HDAC6 and neoplasm: The same findings were reported with SS-208, another HDAC6 inhibitor, showing impaired tumor growth in a syngeneic melanoma mouse model mediated by immune-related antitumor activity, as evidenced by increased infiltration of CD8+ and NK+ T cells along with enhanced M1 to M2 macrophages ratio in the tumor microenvironment [38].